Systemic Sclerosis
An Introduction to Systemic Sclerosis
Systemic sclerosis (SSc) is a rare, life-threatening, rheumatologic autoimmune disease characterised by fibrosis of the skin and multiple organ targets. Treatment strategies involve immunosuppressive and antifibrotic drugs but their efficacy is modest. Haematopoietic stem-cell transplantation reduces long-term mortality, but confers the risk of treatment-related mortality. Nintedanib has been approved to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with SSc, but does not affect skin fibrosis. Many novel therapeutic targets are emerging, including interleukin (IL) -6 (tocilizumab), IL-4 and IL-13, B cell pathology, and the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. However, there remains no approved targeted therapies.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Advances continue to be made in the treatment of systemic sclerosis (SSc, also termed ‘scleroderma’); however, it remains a challenging disease for both patients and for the clinicians caring for them. The purpose of this review is to highlight these ...
The SENSCIS Trial (NCT02597933) was a phase 3 randomised, double-blind, placebo controlled study, which investigated the efficacy and safety of nintedanib in the treatment of patients with systemic sclerosis associated interstitial lung disease. In this touchIMMUNOLOGY interview, it was a pleasure ...
It was an absolute pleasure to speak with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around the initial safety and clinical responses of patients with juvenile-onset systemic sclerosis treated with CD34...
In this interview, we talk with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around CD34-selected peripheral blood ASCT in patients with juvenile-onset systemic sclerosis (NCT03630211). This information is brought to ...
touchIMMUNOLOGY caught up with Dinesh Khanna (University of Michigan, Ann Arbor, MI, USA) to discuss the results of the NOVESA Phase 2a study of ziritaxestat in cutaneous systemic sclerosis (NCT03798366). His abstract entitled ‘A Phase 2a Randomized, Double-blind, Placebo-controlled Study ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
